Pixantrone Novuspharma

IDrugs

Volumn 6, Issue 5, 2003, Pages 486-490

  Borchmann, Peter ^a   Reiser, Marcel ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; BBR 2278; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; DOXORUBICIN LIPID COMPLEX; DRUG METABOLITE; METHYLPREDNISOLONE; MITOXANTRONE; PIXANTRONE; PLACEBO; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HUMAN; INHIBITION KINETICS; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; REVIEW; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VOMITING;

ANIMALS; DNA TOPOISOMERASES, TYPE II; HEMATOLOGIC NEOPLASMS; HUMANS; ISOQUINOLINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 0038519122     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 154042 BBR 2778, a novel aza-anthracenedione: Preclinical toxicological evaluation. Cavalletti E, Crippa L, Melloni E, Bellini O, Tognella S, Giulini FC Proc Annu Meet Am Assoc Cancer Res 1993 34 Abs 2227
2. 157263 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore modified antitumour anthracene-9,10-diones: Synthesis and antitumour evaluations. Krapcho AP, Petry ME, Getahun Z, Landi JJ, Stallman J, Polsenberg JF, Gallagher CE, Maresch MJ, Hacker MP J Med Chem 1994 37 6 828-837
3. 193051 Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Hazelhurst LA, Krapcho AP, Hacker MP Biochem Pharmacol 1995 50 7 1087-1094
4. 294275 A clinical phase I study of the novel anthracenedione analogue, BBR 2778, administered intravenously, 3 weekly. Jodrell DI, Bowman A, Rye R, Dawson L, Byrne B, Gamba E, Smyth JF Ann Oncol 1998 9 2 Abs 451
5. 300151 Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, Oliva A, Spinelli S, Krapcho AP, Giuliani FC, Zunino F Mol Pharmacol 1995 48 1 30-38
6. 309100 Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP Biochem Pharmacol 1993 46 2 265-271
7. 309102 Aza and diaza biosteric anthracene-9,10-diones as antitumor agents. Krapcho AP, Maresch MJ, Hacker MP, Menta E, Oliva A, Guiliani FC, Spinelli S Acta Biochim Pol 1995 42 4 427-432
8. 309104 Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: Aza-anthracenediones. Hazlehurst L, Krapcho AP, Hacker MP Cancer Lett 1995 91 1 115-124
9. 309106 Anthracene-9,10-diones and aza biosteres as antitumor agents. Krapcho AP, Maresch MJ, Hacker MP, Hazlehurst L, Menta E, Oliva A, Spinelli S, Beggiolin G, Giuliani FC, Pezzoni G, Tognella S Curr Med Chem 1995 2 4 803-824
10. 310078 Phase-1 study of BBR2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin lymphomas. Borchmann P, Knippertz R, Schnell R, Gamba E, Diehl V, Engert A Blood 1998 92 10 Suppl 1 Abs 4004
11. 320982 Catalytic inhibitors of DNA topoisomerase II. Andoh T, Ishida R Biochim Biophys Acta Gene Struct Expr 1998 1400 1-3 155-171
12. 322558 Phase I and pharmacokinetic study of BBR 2778, a novel aza-anthracenedione, in patients with advanced solid tumors. Faivre S, Raymond E, Gatineau M, Buthaut X, Boige V, Bernareggi A, Rixe O, Mekhaldi S, Pautier P, Le Chevalier T, Ducreux M et al Proc Annu Meet Am Assoc Cancer Res 1999 40 Abs 772
13. 323943 A phase I study of a new aza-anthracenedione (BBR2778) in patients with refractory non Hodgkin's lymphoma. Borchmann P, Knippertz R, Schnell R, Huebel K, Sieber M, Diehl V, Engert A Ann Hematol 1998 77 Suppl S146
14. 324869 Clinical pharmacokinetics of BBR-2778 in patients with malignant lymphoma. Bernareggi A, Torti L, Ratti E, Camboni MG, Spinelli S, Borchmann P, Diehl V, Engert A Proc Am Soc Clin Oncol 1999 18 Abs 730
15. 327178 BBR-2778, a novel anthracenedione analog: Neutropenia is dose limiting in a phase I study of three-weekly administration. Bowman A, Jodrell DI, Rye R, Dawson L, Byrne B, Gamba E, Camboni G, Bernareggi A, Smyth JF Proc Am Soc Clin Oncol 1999 18 Abs 784
16. 344618 Biopartnering - Novuspharma SpA. Ann Biopartnering Europe Meet 1999 October 18-19
17. 351132 Pharmacokinetics and clinical results of the new aza-anthracenedione BBR2778 in patients with advanced non-Hodgkin lymphomas. Borchmann P, Knippertz R, Schnell R, Camboni G, Bernareggi A, Diehl V, Engert A Blood 1999 94 10 4364
18. 356481 Pharmacokinetics and clinical results of the new aza-anthracenedione BBR2778 in patients with advanced non-Hodgkin lymphomas. Borchmann P, Knippertz R, Schnell R, Camboni G, Bernareggi A, Engert A Blood 1999 94 10 Suppl 1; Pt 2 258b
19. 361529 Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: Effects of the relative positioning of the side chains. Sissi C, Moro S, Zagotto G, Ellis M, Krapcho AP, Mehta E, Palumbo M Anticancer Drug Res 1999 14 265-274
20. 370836 Roche Holdings 1998 - Year of transition. Deutsche Morgan Grenfell Analyst Report 1998 May 07
21. 371426 Drug development pipeline: BBR-3438, BBR-3576 and BBR-2778. Novuspharma SpA Company Communication 2000 June 20
22. 400270 Novuspharma SpA announces financial results for the year ended 31 December 2000. Novuspharma SpA Press Release 2001 February 27
23. 413644 Novuspharma SpA granted IND status for BBR 2778 in the US. Novuspharma SpA Press Release 2001 June 26
24. 422285 Novuspharma's BBR-2778 shows potential for MS. Novuspharma SpA Press Release 2001 September 14
25. 423790 Novuspharma announces positive phase II results for BBR 2778 in non-Hodgkin's lymphoma. Novuspharma SpA Press Release 2001 October 01
26. 429242 Novuspharma SpA announces financial results for the third quarter ended 30 September 2001. Novuspharma SpA Press Release 2001 November 13
27. 432891 Novuspharma presents final data from phase II trial with lead product BBR 2778 for Non-Hodgkin's Lymphoma at ASH. Novuspharma SpA Press Release December 09
28. 441354 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdullah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes I et al N Engl J Med 2002 346 4 235-242
29. 445739 Novuspharma begins BBR-2778 phase III study. Novuspharma SpA Press Release 2002 April 04
30. 441773 Novuspharma SpA announces financial results for the year ended 31 December 2001. Novuspharma SpA Press Release 2002 February 28
31. 455987 BBR-2778 shows promise in MS. Novuspharma SpA Press Release 2002 June 25
32. 472446 Novuspharma reveals phase I plans for pixantrone in MS. Novuspharma SpA Press Release 2002 December 02
33. 475078 Activity and safety of the new aza-anthracenedione BBR 2778 in patients with relapsed non-Hodgkin lymphomas. Borchmann P, Morschhauser F, Schnell R, Kutz K, Barbieri P, Camboni GM, Engert A Blood 2002 100 11 Abs 4752
34. 479565 PEGylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Aviles A, Neri N, Castaneda C, Talavera A, Huerta-Guzman J, Gonzales M Med Oncol 2002 19 1 55-58
35. 480325 Novuspharma progresses in 2002. Novuspharma SpA Press Release 2003 March 03
36. 480900 Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Sarris AH, Jiang Y, Tsimberidou AM, Thomaides A, Rassidakis GZ, Ford RJ, Medeiro LJ, Cabanillas F, McLaughlin P. Semin Oncol 2002 29 1 (Suppl 2) 48-55
37. 480904 Cyclophosphamide, PEGylated liposomal doxorubicin (Caelys), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphomas: Results from a prospective phase II study. Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, De Otezya JP, Arranz R, Terol MJ, Sierra J, San Miguel JF Haematologica 2002 87 8 822-827
38. 480905 PEGylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Tsavaris N, Kosmas C, Vadiaka M, Giannouli S, Siakantaris MP, Vassilakopoulos T, Pangalis GA Anticancer Res 2002 22 3 1845-1848
39. 481012 The pharmacokinetics and metabolism of mitoxantrone in man. Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL Invest New Drugs 1985 3 2 109-116
40. 482189 Phase-II study of BBR 2778, a new aza-anthracenedione, in patients with relapsed aggressive non-Hodgkin lymphomas. Borchmann P, Morschhauser F, Schnell R, Harousseau JL, Gisselbrecht C, Rudolph C, Wilhelm W, Derigs H, Kutz H, Leynardier D, Verdi E et al Blood 2001 98 11 Abs 1441
41. 483098 Global Biotechnology Quarterly. SG Cowen Securities Corp 2003 March 01
42. 483175 Pipeline presentation: Pixantrone - Additional data. Novuspharma SpA Company Presentation 2003 March 25
43. 483280 Investigator's brochure. Novuspharma SpA Company Brochure 2002 July 15